The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Antibodies for the treatment of MDS: magrolimab & sabatolimab
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses up-and-coming antibodies under investigation for the treatment of myelodysplastic syndromes (MDS) in the first-line setting, highlighting key clinical trials. Dr Garcia-Manero comments on magrolimab, which is currenly being evaluating in the ENHANCE trial (NCT04313881), and sabatolimab, which is under investigation in the STIMULUS-MDS1 (NCT03946670) and STIMULUS-MDS2 (NCT04266301) studies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
